File Download
  Links for fulltext
     (May Require Subscription)

Article: Impact of Introducing Infliximab Biosimilars on Total Infliximab Consumption and Originator Infliximab Prices in Eight Regions: An Interrupted Time-Series Analysis

TitleImpact of Introducing Infliximab Biosimilars on Total Infliximab Consumption and Originator Infliximab Prices in Eight Regions: An Interrupted Time-Series Analysis
Authors
Issue Date23-Mar-2023
PublisherSpringer
Citation
BioDrugs, 2023, v. 37, n. 3, p. 409-420 How to Cite?
Abstract

Objective: We aimed to assess whether the introduction of the first infliximab biosimilar was associated with changes in overall infliximab consumption (originator and biosimilars) and price changes to the originator infliximab.

Methods: An interrupted time series analysis using infliximab sales data from 2010 to 2020 from the IQVIA Multinational Integrated Data Analysis System for eight selected regions: Australia, Canada, Hong Kong, Korea, India, Japan, the UK, and the USA. Quarterly measures of infliximab consumption and list prices were respectively defined as the number of standard units (SU)/1000 inhabitants and as 2020 USA dollars (USD)/SU.

Results: Following the introduction of infliximab biosimilars, overall infliximab consumption increased in Australia [immediate change: 0.145 SU/1000 inhabitants (P = 0.014); long-term change: 0.022 SU/1000 inhabitants per quarter (P < 0.001)], Canada [immediate change 0.415 (P = 0.008)], the UK [long-term change 0.024 (P < 0.001)], and Hong Kong [immediate change: 0.042 (P < 0.001)]. The list price of originator infliximab also decreased following biosimilar introduction in Australia [immediate change: - 187.84 USD/SU (P < 0.001); long-term change - 6.46 USD/SU per quarter (P = 0.043)], Canada [immediate change: - 145.58 (P < 0.001)], the UK [immediate change: - 34.95 (P = 0.010); long-term change: - 4.77 (P < 0.001)], and Hong Kong [long-term change: - 4.065 (P = 0.046)]. Consumption and price changes were inconsistent in India, Japan, Korea, and the USA.

Conclusions: Introduction of the first infliximab biosimilar was not consistently associated with increased consumption across regions. Additional policy and healthcare system interventions to support biosimilar infliximab adoption are needed.


Persistent Identifierhttp://hdl.handle.net/10722/329091
ISSN
2021 Impact Factor: 7.744
2020 SCImago Journal Rankings: 1.919

 

DC FieldValueLanguage
dc.contributor.authorPeng, K-
dc.contributor.authorBlais, JE-
dc.contributor.authorPratt, NL-
dc.contributor.authorGuo, JJ-
dc.contributor.authorHillen, JB-
dc.contributor.authorStanford, T-
dc.contributor.authorWard, M-
dc.contributor.authorLai, ECC-
dc.contributor.authorShin, JY-
dc.contributor.authorTong, XN-
dc.contributor.authorFan, M-
dc.contributor.authorCheng, FWT-
dc.contributor.authorWu, J-
dc.contributor.authorYeung, WWY-
dc.contributor.authorLau, CS-
dc.contributor.authorLeung, WK-
dc.contributor.authorWong, ICK-
dc.contributor.authorLi, X-
dc.date.accessioned2023-08-05T07:55:13Z-
dc.date.available2023-08-05T07:55:13Z-
dc.date.issued2023-03-23-
dc.identifier.citationBioDrugs, 2023, v. 37, n. 3, p. 409-420-
dc.identifier.issn1173-8804-
dc.identifier.urihttp://hdl.handle.net/10722/329091-
dc.description.abstract<div><p><strong>Objective: </strong> We aimed to assess whether the introduction of the first infliximab biosimilar was associated with changes in overall infliximab consumption (originator and biosimilars) and price changes to the originator infliximab.</p><p><strong>Methods: </strong> An interrupted time series analysis using infliximab sales data from 2010 to 2020 from the IQVIA Multinational Integrated Data Analysis System for eight selected regions: Australia, Canada, Hong Kong, Korea, India, Japan, the UK, and the USA. Quarterly measures of infliximab consumption and list prices were respectively defined as the number of standard units (SU)/1000 inhabitants and as 2020 USA dollars (USD)/SU.</p><p><strong>Results: </strong> Following the introduction of infliximab biosimilars, overall infliximab consumption increased in Australia [immediate change: 0.145 SU/1000 inhabitants (P = 0.014); long-term change: 0.022 SU/1000 inhabitants per quarter (P < 0.001)], Canada [immediate change 0.415 (P = 0.008)], the UK [long-term change 0.024 (P < 0.001)], and Hong Kong [immediate change: 0.042 (P < 0.001)]. The list price of originator infliximab also decreased following biosimilar introduction in Australia [immediate change: - 187.84 USD/SU (P < 0.001); long-term change - 6.46 USD/SU per quarter (P = 0.043)], Canada [immediate change: - 145.58 (P < 0.001)], the UK [immediate change: - 34.95 (P = 0.010); long-term change: - 4.77 (P < 0.001)], and Hong Kong [long-term change: - 4.065 (P = 0.046)]. Consumption and price changes were inconsistent in India, Japan, Korea, and the USA.</p><p><strong>Conclusions: </strong> Introduction of the first infliximab biosimilar was not consistently associated with increased consumption across regions. Additional policy and healthcare system interventions to support biosimilar infliximab adoption are needed.</p></div>-
dc.languageeng-
dc.publisherSpringer-
dc.relation.ispartofBioDrugs-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.titleImpact of Introducing Infliximab Biosimilars on Total Infliximab Consumption and Originator Infliximab Prices in Eight Regions: An Interrupted Time-Series Analysis-
dc.typeArticle-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.1007/s40259-023-00589-3-
dc.identifier.scopuseid_2-s2.0-85150613052-
dc.identifier.volume37-
dc.identifier.issue3-
dc.identifier.spage409-
dc.identifier.epage420-
dc.identifier.eissn1179-190X-
dc.identifier.issnl1173-8804-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats